Andrea De Gaetano

Prof. Andrea De Gaetano

CNR-IRIB Istituto per la Ricerca e l'Innovazione Biomedica, Palermo, Sicilia, Italy
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2012 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
GMGeltrude Mingrone
Geltrude Mingrone
SPSimona Panunzi
Simona Panunzi
Andrea De GaetanoAndrea De Gaetano
Andrea De Gaetano
CGCaterina Guidone
Caterina Guidone
AIAmerigo Iaconelli
Amerigo Iaconelli
FRFrancesco Rubino
Francesco Rubino
Roux-en-Y gastric bypass and biliopancreatic diversion can markedly ameliorate diabetes in morbidly obese patients, often resulting in disease remission. Prospective, randomized trials comparing these procedures with medical therapy for the treatment of diabetes are needed.

1 September 2015 in The Lancet
Verified
Journal Article
Closed access
GMGeltrude Mingrone
Geltrude Mingrone
SPSimona Panunzi
Simona Panunzi
Andrea De GaetanoAndrea De Gaetano
Andrea De Gaetano
CGCaterina Guidone
Caterina Guidone
AIAmerigo Iaconelli
Amerigo Iaconelli
FRFrancesco Rubino
Francesco Rubino

1 August 2014 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
SMSalvatore Maurizio Maggiore
Salvatore Maurizio Maggiore
FIFrancesco Antonio Idone
Francesco Antonio Idone
RVRosanna Vaschetto
Rosanna Vaschetto
RFRossano Festa
Rossano Festa
ACAndrea Cataldo
Andrea Cataldo
MAMassimo Antonelli
Massimo Antonelli
Rationale: Oxygen is commonly administered after extubation. Although several devices are available, data about their clinical efficacy are scarce. Objectives: To compare the effects of the Venturi mask and the nasal high-flow (NHF) therapy on PaO2/FiO2SET ratio after extubation. Secondary endpoints were to assess effects on patient discomfort, adverse events, and clinical outcomes. Methods: Randomized, controlled, open-label trial on 105 patients with a PaO2/FiO2 ratio less than or equal to 300 immediately before extubation. The Venturi mask (n = 52) or NHF (n = 53) were applied for 48 hours postextubation. Measurements and Main Results: PaO2/FiO2SET, patient discomfort caused by the interface and by symptoms of airways dryness (on a 10-point numerical rating scale), interface displacements, oxygen desaturations, need for ventilator support, and reintubation were assessed up to 48 hours after extubation. From the 24th hour, PaO2/FiO2SET was higher with the NHF (287 ± 74 vs. 247 ± 81 at 24 h; P = 0.03). Discomfort related both to the interface and to airways dryness was better with NHF (respectively, 2.6 ± 2.2 vs. 5.1 ± 3.3 at 24 h, P = 0.006; 2.2 ± 1.8 vs. 3.7 ± 2.4 at 24 h, P = 0.002). Fewer patients had interface displacements (32% vs. 56%; P = 0.01), oxygen desaturations (40% vs. 75%; P < 0.001), required reintubation (4% vs. 21%; P = 0.01), or any form of ventilator support (7% vs. 35%; P < 0.001) in the NHF group. Conclusions: Compared with the Venturi mask, NHF results in better oxygenation for the same set FiO2 after extubation. Use of NHF is associated with better comfort, fewer desaturations and interface displacements, and a lower reintubation rate. Clinical trial registered with www.clinicaltrials.gov (NCT 01575353).

17 February 2000 in Journal of Mathematical Biology
Verified
Journal Article
Closed access
PDF file
Andrea De GaetanoAndrea De Gaetano
Andrea De Gaetano
OAOvide Arino
Ovide Arino

1 September 2006 in Critical Care Medicine
Verified
Journal Article
Closed access
AMAndrea Morelli
Andrea Morelli
JTJean Louis Teboul
Jean Louis Teboul
SMSalvatore Maurizio Maggiore
Salvatore Maurizio Maggiore
AVAntoine Vieillard-Baron
Antoine Vieillard-Baron
Monica RoccoMonica Rocco
Monica Rocco
MWMartin Westphal
Martin Westphal
Acute respiratory distress syndrome (ARDS) is frequently associated with increased pulmonary vascular resistance and thus with systolic load of the right ventricle. We hypothesized that levosimendan, a new calcium sensitizer with potential pulmonary vasodilator properties, improves hemodynamics by unloading the right ventricle in patients with ARDS. Prospective, randomized, placebo-controlled, pilot study. Twenty-two-bed multidisciplinary intensive care unit of a university hospital. Thirty-five patients with ARDS in association with septic shock. Patients were randomly allocated to receive a 24-hr infusion of either levosimendan 0.2 μg/kg/min (n = 18) or placebo (n = 17). Data from right heart catheterization, cardiac magnetic resonance, arterial and mixed venous oxygen tensions and saturations, and carbon dioxide tensions were obtained before and 24 hrs after drug infusion. At a mean arterial pressure between 70 and 80 mm Hg (sustained with norepinephrine infusion), levosimendan increased cardiac index (from 3.8 ± 1.1 to 4.2 ± 1.0 L/min/m2) and decreased mean pulmonary artery pressure (from 29 ± 3 to 25 ± 3 mm Hg) and pulmonary vascular resistance index (from 290 ± 77 to 213 ± 50 dynes/s/cm5/m2; each p < .05). Levosimendan also decreased right ventricular end-systolic volume and increased right ventricular ejection fraction (p < .05). In addition, levosimendan increased mixed venous oxygen saturation (from 63 ± 8 to 70 ± 8%; p < .01). This study provides evidence that levosimendan improves right ventricular performance through pulmonary vasodilator effects in septic patients with ARDS. A large multiple-center trial is needed to investigate whether levosimendan is able to improve the overall prognosis of patients with sepsis and ARDS.

11 July 2013 in Diabetes Care
Verified
Journal Article
Open access
PDF file
JSJoanne Sloan-Lancaster
Joanne Sloan-Lancaster
EAEyas Abu-Raddad
Eyas Abu-Raddad
JPJohn Polzer
John Polzer
JMJeffrey W. Miller
Jeffrey W. Miller
JSJoel C. Scherer
Joel C. Scherer
WLWilliam H. Landschulz
William H. Landschulz
OBJECTIVE: Inflammation is associated with pancreatic β-cell apoptosis and reduced insulin sensitivity. Literature suggests that interleukin (IL)-1β may contribute to the pathogenesis of type 2 diabetes mellitus (T2DM). This study aimed to determine the efficacy, safety, and tolerability of LY2189102, a neutralizing IL-1β antibody, in T2DM patients. RESEARCH DESIGN AND METHODS: Phase II, randomized, double-blind, parallel, placebo-controlled study of subcutaneous LY2189102 (0.6, 18, and 180 mg) administered weekly for 12 weeks in T2DM patients on diet and exercise, with or without approved antidiabetic medications. RESULTS: LY2189102 reduced HbA1c at 12 weeks (adjusted mean differences versus placebo: −0.27, −0.38 and −0.25% for 0.6, 18 and 180 mg doses, respectively), and fasting glucose at multiple time points compared with placebo. LY2189102 also reduced postprandial glycemia, and inflammatory biomarkers, including hs-CRP and IL-6. LY2189102 was generally well tolerated. CONCLUSIONS: Weekly subcutaneous LY2189102 for 12 weeks was well tolerated, modestly reduced HbA1c and fasting glucose, and demonstrated significant anti-inflammatory effects in T2DM patients. Neutralizing IL-1β holds promise as a convenient adjuvant treatment for T2DM.